On May 19, 2025, Alaunos Therapeutics, Inc. entered into an agreement with Mast Hill Fund to sell up to $25 million in common stock, enabling sales over the next 24 months at the company's discretion. The agreement includes a warrant for 79,900 shares at an exercise price of $4.00.